THE LEADERSHIP TEAM AT CROWN HAVE A DEEP UNDERSTANDING OF THE PHARMACEUTICAL INDUSTRY HAVINGÂ SIGNIFICANT EXPERIENCE BUILDING AND OPERATING BUSINESSES AND MAJOR DEPARTMENTS WITHIN THE TOP US PHARMACEUTICAL R&D AND PRE-CLINICAL PROGRAMS. OUR OBJECTIVE IS TO DELIVER FAST, COST-EFFECTIVE PRE-CLINICAL RESEARCH SERVICES FOR PHARMACEUTICAL, BIOTECH AND MEDICAL DEVICE COMPANIES.
Guo Liang Yu
Dr. Yu co-founded Epitomics Inc., an antibody based Biotechnology Company recently acquired by Abcam at $170 M. He served as Chairman, President and CEO of Epitomics Inc. for 10 years. Dr. Yuâs success is driven by his scientific curiosity and a passion to translate scientific discovery to real products. His challenge is to balance his time between science and business, fun and work, family and community.
He came from China to pursue advanced training after graduated from Fudan University in 1984. He obtained his Ph.D. in UC Berkeley where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburnâs lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery. Dr. Yu then joined Dr. Frederick Ausubelâs lab at Harvard to pursue the question how plants defend themselves against pathogens without an immune system. He identified the first plant disease resistance gene.
In 1993, instead of continue his academic advancement, Dr. Yu became one of the first Senior Scientists in Human Genome Sciences Inc., when genomics is still in its infancy, identifying human genes for drug discovery. Among several important drug targets he studied, BLys was the first successfully genomic target for the development of a lupus antibody drug Benlysta approved by FDA in 2010.
In 1998, Dr. Yu was attracted to identify plant genes with economic value in agriculture and in bio-energy. He was SVP of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors. Several valuable traits such as enhanced crop yield, disease resistance and drought tolerance were identified. It was expected that some of the technologies will be commercialized in 2014.
Guo-Liang has co-authored 40 peer-reviewed scientific articles which are referenced by the scientific community 6000 times. Guo-Liang is also a co-inventor of more than 200 patents. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and serves on the boards of several professional organizations including Bayhelix, CABS, National Foundation of Cancer Research, Ray Wu Memorial Foundation, University of Pacific in the US and China.
Dr. Yu is generous in coaching young entrepreneurs and also serves on the board of directors for six start-up companies.
Alex Wu, Ph.D.
CHIEF EXECUTIVE OFFICER
Dr. Alex Wu has overÂ in the life science industry and academic research. Before co-founding Crown Bioscience, he was CBO of Starvax International, a development stage biotech company specialized in oncology and infectious diseases. Prior to Starvax, Alex was with Burrill & Company, a world leading life sciences merchant bank and venture capital firm. Before joining the venture capital industry, Alex was involved in several start-ups, one of which was Unimicro Technologies, Inc. He also worked for Hoffmannn-La Roche as Manager of Business Development and Strategic Planning. Dr. Wu received B.S. from Fudan University in Shanghai, China and Ph.D. in Molecular and Cell Biology and MBA from the University of California, Berkeley. He conducted post-doctoral research at Stanford University.
Jean-Pierre Wery, Ph.D
Prior to joining CrownBio, Dr. Wery was Chief Scientific Officer at Monarch Life Sciences, a company dedicated to the discovery and development of protein biomarkers. Prior to joining Monarch, Dr. Wery spent three years at Vitae Pharmaceuticals, Inc. where he was VP of Computational Drug Discovery. Before joining Vitae he worked for 12 years at Eli Lilly and Company in various scientific and management positions. Dr. Wery received his B.S. and Ph.D. in Physics from the U. of Liege, Belgium. Following his Ph.D., he did postdoctoral studies at Purdue University with Prof. Jack Johnson. Dr. Wery has authored more than 50 abstracts and publications.
Chuan Joe Shih, Ph.D
EXECUTIVE VP INTEGRATED DRUG DISCOVERY
Prior to joining Crown, Dr. Joe Shih, Ph.D., was a Distinguished Lilly Scholar of Discovery Chemistry Research and Technology at Lilly Research Laboratories (LRL), a Division of Eli Lilly and Company. Joe received a doctorate in Organic Chemistry from The Ohio State University in 1982. He was also awarded a Bachelor of Science in Chemistry from the National Chung-Hsing University, Taiwan in 1976, and a Master of Science in Organic Chemistry from The Ohio State University in 1979. Dr. Shih completed a postdoctoral fellowship at Harvard University under Nobel Laureate Professor E. J. Corey from 1982 to 1984. Following his postdoctoral studies, he joined Lilly as a Senior Organic Chemist in 1984. He was promoted to Research Scientist in 1989, to Senior Research Scientist in 1993, to Research Advisor in 1999, to Distinguished Research Fellow in 2004 and to Distinguished Lilly Scholar in 2007. During his tenure at Eli Lilly, Dr. Shih has distinguished himself as a premier drug hunter by contributing to many LRL oncology drug discovery efforts. Through his collaboration with Princeton University, Dr. Shih contributed to the successful antifolate drug discovery program that has led to the development of ALIMTA([R]), a blockbuster anticancer agent approved by various regulatory agencies around the globe for the treatment of mesothelioma and non-small cell lung cancer. Dr Shih is a co-inventor of ALIMTA([R]) and a pioneer in the elucidation of the unique “multi-targeted antifolate” mechanism of action of ALIMTA[R]. Dr. Shih was awarded the 2006 American Chemical Society “Heroes of Chemistry” Award for his role in the discovery and development of ALIMTA([R]). Dr. Shih was also instrumental in leading various medicinal chemistry and drug discovery initiatives and efforts in the identification of several novel anticancer agents currently in the Lilly Oncology pipeline. Dr. Shih is widely recognized for his expertise in cancer and medicinal chemistry research. He is frequently invited to lecture and chair sessions at national and international meetings. Dr. Shih has authored and co-authored more than 180 scientific publications and presentations and holds numerous patents.
CHIEF FINANCIAL OFFICER
Mr. Bing Zhu is responsible for overseeing our corporate finance and IT departments. From 2010 to 2013, Mr. Zhu was the chief strategy officer of LDK Solar Co., Ltd., a company listed on the New York Stock Exchange, and concurrently an executive director and the chief financial officer of LDK Silicon & Chemicals Technology Co., Ltd., a subsidiary majority owned by LDK Solar Co., Ltd. From 2008 to 2010, Mr. Zhu was the chief financial officer and a director of Chemspec International Ltd., a company listed on the New York Stock Exchange. From 2005 to 2008, Mr. Zhu was with Canadian Solar Inc., whose head office is based in Suzhou, China, as a director and the chief financial officer. Prior to that, Mr. Zhu worked for four years in commercial banking in Toronto, Canada. From 1996 to 2000, Mr. Zhu was the Shanghai chief representative of Raytheon Corporation. From 1993 to 1996, Mr. Zhu was a corporate banking account manager for Banque Indosuez. Mr. Zhu holds a master of business administration degree from China Europe International Business School and a bachelorâs degree in business management from Zhejiang University of Technology in China.
Yining Qi, M.D., M.PH, MBA
SENIOR VP OF OPERATION AND GENERAL MANAGER OF CROWNBIO TAICANG FACILITY
Dr. Yining QiÂ M.D., M.PH, MBAÂ has 20 years experience working in Pharmaceutical, Medical Device and CRO industry. He has extensive experience in managing operations and various process improvement projects. Prior to joining CrownBio, he was Executive Director at WuXi AppTec Preclinical Facility and was responsible for Technical Operations, Client Services and Project Management. He had built an effective study planning and tracking system as well as led electronic data capture system validation project. He worked at Merck Research Lab as Research Fellow / Group Leader in Technical Operation of Safety Assessment Division leading several data system validation and process improvement projects. During his 15 years in US, he also worked for BD and Johns Hopkins University and SITEK research lab. Before he went to US, he was Director of Pharmacology and Toxicology lab at Beijing Institute for Drug Control of SFDA. He had been involved in many new drug development projects and IND & NDA application reviewing processes. He received Medical Degree and MPH from Shanxi Medical University and MBA from Rutgers University in Pharmaceutical Management. Dr. Qi is also a certified Six Sigma Green Belt.
Jiping Zha, MD/Ph.D.
SENIOR VP DRUG DISCOVERY TECHNOLOGY, INTEGRATED DRUG DISCOVERY & DEVELOPMENT SERVICE BUSINESS UNIT
Dr. Zha is a physician scientist with 21 years of extensive and in-depth experience in cancer biology. He received Howard Temin Award from National Cancer Institute in 1999 and used to be an instructor and an assistant professor at Harvard Medical School and the University of Texas Southwestern Medical Center at Dallas, respectively. He has 33 publications in high-impact scientific journals, such as Cell, Science and Nature, and 4 pending patent applications. He joined Genentech as a scientist in 2003, and led a therapeutic antibody program from its inception to IND filing and clinical testing. In addition, he played key roles in the development of multiple biomarker programs, one of which has enabled the success of a recent PhII trial for a targeted therapy in non-small cell lung cancer. Dr. Zha is a licensed physician in the State of California and board-certified in Anatomic Pathology.
Yixin (Jim) Wang, M.D.
SENIOR VP CARDIOVASCULAR AND METABOLIC DISEASES (CVMD) RESEARCH; PRESIDENT INTERNATIONAL INSTITUTE OF BIOMEDICAL RESEARCH (IIBR), A CROWN BIOSCIENCE COMPANY
Dr. Wang started his academic career as a postdoctoral researcher in Boston University in 1987-1990, later as an assistant professor in the University of Tennessee at Memphis in 1992-1996 . He has since worked in several major pharmas (GSK, Roche, Schering/Bayer AG) as a scientist, senior scientist and principle scientist during 1990 – 2008 and in a startup biotech (Arete Therapeutics, Inc.) as a director of Pharmacology in 2008 – 2009. In 2010, he joint Crown Bioscience as a head of CVMD research. He has been working in cardiovascular and metabolic research area with ~100 publications in research articles, invited reviewers, book chapters, and patent applications in the areas of diabetes and metabolic diseases, heart and renal failure, hypertension, thrombosis, hemophilia, atherosclerosis and dyslipidemia, hemodynamics, pharmacokinetics and pharmacodynamics, safety pharmacology, etc. He has been involving in all stages of pharmaceutical R&D, from early stage of target discovery and validation, compound (large and small molecules) discovery, selection and profilng, IND filing and clinical trials in Phase I & II.
Henry Li, Ph.D.
VP TRANSLATIONAL ONCOLOGY
Henry QX Li, Ph.D. currently leads Crownâs Translational Oncology Division with platforms built on patient derived xenograft (PDX). Prior to Crown, Dr. Li has over 20 years of biopharmaceutical, as well as academic R&D, experiences in cancer and viral infection, including leadership roles as R&D director/senior director roles in several US-based biotech companies. Dr. Li currently also holds visiting Professor position at Peking University-State Key Laboratory. He earned his Ph.D. in Molecular Biology/Biochemistry from University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 50 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.
Boyu Zhong, Ph.D.
VP MEDICINAL CHEMISTRY
Dr. Boyu Zhong is a versatile research scientist with over 20 years of R&D experience in industry and academy. Prior to joining Crown in 2010, Dr. Zhong was a Principal Research Scientist of Discovery Chemistry Research and Technology at Lilly Research Laboratories (LRL), a Division of Eli Lilly and Company. His expertise is on organic synthesis, bioorganic chemistry, molecular design, lead generation and lead optimization technology, and new drug discovery leadership. He has significantly contributed to many oncology drug discovery efforts. He published over 30 research papers and patent applications. Dr. Zhong did Ph.D. training in Professor Richard B. Silvermanâs lab at Northwestern University and completed his postdoctoral studies with Professor Andrew G. Myers in California Institute of Technology and Harvard University. He also possesses degrees of Bachelor in Chemical Engineering (Hefei University of Technology), Master in Chemical Engineering (Research Institute of Petroleum Processing), and Master of Science in Chemistry (Cleveland State University). He worked once as a chemical engineer in Sinopec.
Sam Lou, MBA.
VP BUSINESS DEVELOPMENT AND INTELLIGENCE
Sam Lou jointed Crown Bioscience as Vice President, Business Development in Greater China in Jan. 2011. Samâs focus and major responsibility include promotion of CrownBioâs New Drug Discovery platform and construction of strategic partnership with major pharma in the region. Prior to Join CrownBio, Sam had been Vice President of CMC Operation at Frontage Lab, where he led the major expansion of CMC operation in China and successfully initiated multiple ANDA development programs helping Chinese pharmaceutical companies going global. Before moving back to Shanghai, Sam had spend 4 years working as President and CEO at WanDong Health Sources Inc. a Beijing based medical device firm specialised in blood salvage equipments and consumables for surgical patients. For the same period of time, Sam also served as Chief Business Advisor for WanDong Medical, a brand name medical equipment manufacturer listed in Shanghai Stock Exchange. From May 2003 through July 2005, Sam was the Chief Operating Officer of Shanghai based Crimson Pharmaceuticals. Crimson is the first China based company utilizing âLicensing and Developmentâ strategy to accelerate innovative drug development in China. Before return to China, Mr. Lou spent twelve years in California serving biopharmaceutical and biotech companies. Sam obtained his training as analytical chemist in a GMP environment at InSite Vision and as development scientist on mAb of BexxarTM and other small molecule anti-cancer drug development at Coulter Pharmaceuticals, California. Sam is an active speaker and panellist in international conferences on biotechnology and pharmaceutical development in China. Mr. Lou obtained BS degree in Chemical Engineering from Tianjin University, China, and MBA from Capella University in Minneapolis, Minnesota, USA.